FDA Brief

Warning letters Drugs

FDA warning letter to

Intercos Europe S.p.A

High riskIssued Aug 15, 2024Posted Aug 20, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.

What happened

FDA inspected the Agrate Brianza drug manufacturing facility from March 11 to 15, 2024. The agency found that the firm made OTC sunscreen drug products without adequate identity testing of incoming glycerin for diethylene glycol (DEG) and ethylene glycol (EG), relied on supplier certificates without establishing their reliability, inadequately investigated microbial excursions, and kept incomplete laboratory records. It also found data integrity problems in the quality system.

What FDA found

  1. The firm did not test each incoming component lot for identity and all specifications; for glycerin, it lacked a DEG/EG identity test and relied on supplier certificates without establishing their reliability.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm failed to thoroughly investigate microbial excursions in its manufacturing system and changed batch records without adequate explanation or investigation.

    21 CFR 211.192
  3. Laboratory records were incomplete, such as missing solvent lot numbers and quantities for a finished-product zinc oxide test, and equipment conditions were not peer-reviewed.

    21 CFR 211.194(a)
  4. The quality system did not adequately ensure the accuracy and integrity of data supporting drug safety, effectiveness, and quality.

    21 CFR parts 210 and 211

What FDA wants

FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with its corrections and preventive actions. The firm must also provide requested risk assessments and testing, including DEG/EG test results from reserve samples within 30 calendar days.

Who should pay attention

  • brands that buy OTC sunscreen drugs from this contract manufacturer
  • companies using glycerin or other high-risk drug components
  • drugmakers relying on supplier certificates of analysis

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk